Loading…
Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis
The p16INK4a tumour suppressor gene, encoding p16 protein, plays a crucial role in regulation of the G1 cell‐cycle phase. To investigate the potential role of p16 in soft tissue leiomyosarcoma (LMS), an immunohistochemical analysis was performed of 77 LMSs for p16 expression. Decreased expression of...
Saved in:
Published in: | The Journal of pathology 2003-11, Vol.201 (3), p.487-495 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 495 |
container_issue | 3 |
container_start_page | 487 |
container_title | The Journal of pathology |
container_volume | 201 |
creator | Kawaguchi, Ken-ichi Oda, Yoshinao Saito, Tsuyoshi Yamamoto, Hidetaka Tamiya, Sadafumi Takahira, Tomonari Miyajima, Kimitaka Iwamoto, Yukihide Tsuneyoshi, Masazumi |
description | The p16INK4a tumour suppressor gene, encoding p16 protein, plays a crucial role in regulation of the G1 cell‐cycle phase. To investigate the potential role of p16 in soft tissue leiomyosarcoma (LMS), an immunohistochemical analysis was performed of 77 LMSs for p16 expression. Decreased expression of the p16 protein was identified in 25 of 77 LMSs (32%). Decreased expression of p16 correlated significantly with large tumour size (p = 0.0038). In a univariate analysis, large tumour size and decreased expression of p16 were statistically significant adverse prognostic factors (p = 0.025 and p = 0.0021, respectively). In a multivariate analysis including conventional clinicopathological parameters, decreased expression of p16 protein was revealed as the only independent unfavourable prognostic factor (p = 0.012). To elucidate the mechanisms of inactivation of the p16INK4a gene, 49 LMSs for which genomic DNA was available were examined; analysis for homozygous deletion, mutation, and promoter hypermethylation was conducted using differential PCR, PCR–SSCP, and methylation‐specific PCR, respectively. Promoter hypermethylation was detected in 11 of 49 LMS cases (22%); homozygous deletion was detected in 3 of 49 cases (6%); and mutation was not recognized in any of the cases studied. Eight of 15 cases (53%) with decreased expression of p16 protein revealed methylation of the p16INK4a gene promoter. Promoter hypermethylation correlated closely with decreased expression and poor prognosis (p = 0.0014 and p = 0.0088, respectively). These results suggest that decreased expression of p16 protein can be considered as an independent reliable prognostic parameter in patients with soft tissue LMS. Furthermore, promoter methylation was more frequent than either homozygous deletion or mutation in this tumour, and promoter methylation was also shown to have a strong association with inactivation of the p16INK4a gene. Copyright © 2003 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/path.1419 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71358717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71358717</sourcerecordid><originalsourceid>FETCH-LOGICAL-i1629-803a8dc6057960938eac50e29bf070c0c531c162bb5a7ea11688605147c4e1cb3</originalsourceid><addsrcrecordid>eNpFkc1u1DAURiMEotPCghdA3sAurZ3EdsyuKvRHDKUSRSytG89Nx5DEqa-Hdl6HJyXRDHRlW98590r-suyN4MeC8-JkhLQ-FpUwz7KF4EblpjbqebaYsiIvK6EPskOin5xzY6R8mR2IShqpVbHI_nxBt4bBU08stMwP4JL_DcmHYX6nNbJRqKvrzxWwOxxwIliHPvTbQBBd6GHGKLSJJU-0wQ9shS4iEK5mk-HjGJFonudCjNhBQmIPPq3ZGEMfEkbWY1pvu91SGCYvhDind0MgT6-yFy10hK_351H2_fzT7dllvvx6cXV2usy9UIXJa15CvXKKS20UN2WN4CTHwjQt19xxJ0vhJrJpJGgEIVRdT7CotKtQuKY8yt7v5k6b7zdIyfaeHHYdDBg2ZLUoZa2FnsC3e3DT9LiyY_Q9xK3996sT8G4PADno2giD8_TEyUJxXsuJO9lxD77D7VPO7VyrnWu1c6325vT2cr5MRr4zPCV8_G9A_GWVLrW0P64vbP1R3miz_GZV-Rf9H6Ym</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71358717</pqid></control><display><type>article</type><title>Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis</title><source>Wiley</source><creator>Kawaguchi, Ken-ichi ; Oda, Yoshinao ; Saito, Tsuyoshi ; Yamamoto, Hidetaka ; Tamiya, Sadafumi ; Takahira, Tomonari ; Miyajima, Kimitaka ; Iwamoto, Yukihide ; Tsuneyoshi, Masazumi</creator><creatorcontrib>Kawaguchi, Ken-ichi ; Oda, Yoshinao ; Saito, Tsuyoshi ; Yamamoto, Hidetaka ; Tamiya, Sadafumi ; Takahira, Tomonari ; Miyajima, Kimitaka ; Iwamoto, Yukihide ; Tsuneyoshi, Masazumi</creatorcontrib><description>The p16INK4a tumour suppressor gene, encoding p16 protein, plays a crucial role in regulation of the G1 cell‐cycle phase. To investigate the potential role of p16 in soft tissue leiomyosarcoma (LMS), an immunohistochemical analysis was performed of 77 LMSs for p16 expression. Decreased expression of the p16 protein was identified in 25 of 77 LMSs (32%). Decreased expression of p16 correlated significantly with large tumour size (p = 0.0038). In a univariate analysis, large tumour size and decreased expression of p16 were statistically significant adverse prognostic factors (p = 0.025 and p = 0.0021, respectively). In a multivariate analysis including conventional clinicopathological parameters, decreased expression of p16 protein was revealed as the only independent unfavourable prognostic factor (p = 0.012). To elucidate the mechanisms of inactivation of the p16INK4a gene, 49 LMSs for which genomic DNA was available were examined; analysis for homozygous deletion, mutation, and promoter hypermethylation was conducted using differential PCR, PCR–SSCP, and methylation‐specific PCR, respectively. Promoter hypermethylation was detected in 11 of 49 LMS cases (22%); homozygous deletion was detected in 3 of 49 cases (6%); and mutation was not recognized in any of the cases studied. Eight of 15 cases (53%) with decreased expression of p16 protein revealed methylation of the p16INK4a gene promoter. Promoter hypermethylation correlated closely with decreased expression and poor prognosis (p = 0.0014 and p = 0.0088, respectively). These results suggest that decreased expression of p16 protein can be considered as an independent reliable prognostic parameter in patients with soft tissue LMS. Furthermore, promoter methylation was more frequent than either homozygous deletion or mutation in this tumour, and promoter methylation was also shown to have a strong association with inactivation of the p16INK4a gene. Copyright © 2003 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.1419</identifier><identifier>PMID: 14595762</identifier><identifier>CODEN: JPTLAS</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Child ; Cyclin-Dependent Kinase Inhibitor p16 - analysis ; Diseases of striated muscles. Neuromuscular diseases ; DNA Mutational Analysis - methods ; Female ; Gene Deletion ; Gene Expression Regulation, Neoplastic - genetics ; Genes, p16 ; Genes, Tumor Suppressor ; Homozygote ; homozygous deletion ; Humans ; immunohistochemistry ; Immunohistochemistry - methods ; leiomyosarcoma ; Leiomyosarcoma - genetics ; Male ; Medical sciences ; Methylation ; Middle Aged ; Neoplasm Proteins - analysis ; Neurology ; p16INK4a ; Polymerase Chain Reaction - methods ; Polymorphism, Single-Stranded Conformational ; Prognosis ; promoter hypermethylation ; Promoter Regions, Genetic - genetics ; Soft Tissue Neoplasms - genetics</subject><ispartof>The Journal of pathology, 2003-11, Vol.201 (3), p.487-495</ispartof><rights>Copyright © 2003 John Wiley & Sons, Ltd.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2003 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15260085$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14595762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawaguchi, Ken-ichi</creatorcontrib><creatorcontrib>Oda, Yoshinao</creatorcontrib><creatorcontrib>Saito, Tsuyoshi</creatorcontrib><creatorcontrib>Yamamoto, Hidetaka</creatorcontrib><creatorcontrib>Tamiya, Sadafumi</creatorcontrib><creatorcontrib>Takahira, Tomonari</creatorcontrib><creatorcontrib>Miyajima, Kimitaka</creatorcontrib><creatorcontrib>Iwamoto, Yukihide</creatorcontrib><creatorcontrib>Tsuneyoshi, Masazumi</creatorcontrib><title>Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>The p16INK4a tumour suppressor gene, encoding p16 protein, plays a crucial role in regulation of the G1 cell‐cycle phase. To investigate the potential role of p16 in soft tissue leiomyosarcoma (LMS), an immunohistochemical analysis was performed of 77 LMSs for p16 expression. Decreased expression of the p16 protein was identified in 25 of 77 LMSs (32%). Decreased expression of p16 correlated significantly with large tumour size (p = 0.0038). In a univariate analysis, large tumour size and decreased expression of p16 were statistically significant adverse prognostic factors (p = 0.025 and p = 0.0021, respectively). In a multivariate analysis including conventional clinicopathological parameters, decreased expression of p16 protein was revealed as the only independent unfavourable prognostic factor (p = 0.012). To elucidate the mechanisms of inactivation of the p16INK4a gene, 49 LMSs for which genomic DNA was available were examined; analysis for homozygous deletion, mutation, and promoter hypermethylation was conducted using differential PCR, PCR–SSCP, and methylation‐specific PCR, respectively. Promoter hypermethylation was detected in 11 of 49 LMS cases (22%); homozygous deletion was detected in 3 of 49 cases (6%); and mutation was not recognized in any of the cases studied. Eight of 15 cases (53%) with decreased expression of p16 protein revealed methylation of the p16INK4a gene promoter. Promoter hypermethylation correlated closely with decreased expression and poor prognosis (p = 0.0014 and p = 0.0088, respectively). These results suggest that decreased expression of p16 protein can be considered as an independent reliable prognostic parameter in patients with soft tissue LMS. Furthermore, promoter methylation was more frequent than either homozygous deletion or mutation in this tumour, and promoter methylation was also shown to have a strong association with inactivation of the p16INK4a gene. Copyright © 2003 John Wiley & Sons, Ltd.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - analysis</subject><subject>Diseases of striated muscles. Neuromuscular diseases</subject><subject>DNA Mutational Analysis - methods</subject><subject>Female</subject><subject>Gene Deletion</subject><subject>Gene Expression Regulation, Neoplastic - genetics</subject><subject>Genes, p16</subject><subject>Genes, Tumor Suppressor</subject><subject>Homozygote</subject><subject>homozygous deletion</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>Immunohistochemistry - methods</subject><subject>leiomyosarcoma</subject><subject>Leiomyosarcoma - genetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylation</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - analysis</subject><subject>Neurology</subject><subject>p16INK4a</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Polymorphism, Single-Stranded Conformational</subject><subject>Prognosis</subject><subject>promoter hypermethylation</subject><subject>Promoter Regions, Genetic - genetics</subject><subject>Soft Tissue Neoplasms - genetics</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkc1u1DAURiMEotPCghdA3sAurZ3EdsyuKvRHDKUSRSytG89Nx5DEqa-Hdl6HJyXRDHRlW98590r-suyN4MeC8-JkhLQ-FpUwz7KF4EblpjbqebaYsiIvK6EPskOin5xzY6R8mR2IShqpVbHI_nxBt4bBU08stMwP4JL_DcmHYX6nNbJRqKvrzxWwOxxwIliHPvTbQBBd6GHGKLSJJU-0wQ9shS4iEK5mk-HjGJFonudCjNhBQmIPPq3ZGEMfEkbWY1pvu91SGCYvhDind0MgT6-yFy10hK_351H2_fzT7dllvvx6cXV2usy9UIXJa15CvXKKS20UN2WN4CTHwjQt19xxJ0vhJrJpJGgEIVRdT7CotKtQuKY8yt7v5k6b7zdIyfaeHHYdDBg2ZLUoZa2FnsC3e3DT9LiyY_Q9xK3996sT8G4PADno2giD8_TEyUJxXsuJO9lxD77D7VPO7VyrnWu1c6325vT2cr5MRr4zPCV8_G9A_GWVLrW0P64vbP1R3miz_GZV-Rf9H6Ym</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Kawaguchi, Ken-ichi</creator><creator>Oda, Yoshinao</creator><creator>Saito, Tsuyoshi</creator><creator>Yamamoto, Hidetaka</creator><creator>Tamiya, Sadafumi</creator><creator>Takahira, Tomonari</creator><creator>Miyajima, Kimitaka</creator><creator>Iwamoto, Yukihide</creator><creator>Tsuneyoshi, Masazumi</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200311</creationdate><title>Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis</title><author>Kawaguchi, Ken-ichi ; Oda, Yoshinao ; Saito, Tsuyoshi ; Yamamoto, Hidetaka ; Tamiya, Sadafumi ; Takahira, Tomonari ; Miyajima, Kimitaka ; Iwamoto, Yukihide ; Tsuneyoshi, Masazumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i1629-803a8dc6057960938eac50e29bf070c0c531c162bb5a7ea11688605147c4e1cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - analysis</topic><topic>Diseases of striated muscles. Neuromuscular diseases</topic><topic>DNA Mutational Analysis - methods</topic><topic>Female</topic><topic>Gene Deletion</topic><topic>Gene Expression Regulation, Neoplastic - genetics</topic><topic>Genes, p16</topic><topic>Genes, Tumor Suppressor</topic><topic>Homozygote</topic><topic>homozygous deletion</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>Immunohistochemistry - methods</topic><topic>leiomyosarcoma</topic><topic>Leiomyosarcoma - genetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylation</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - analysis</topic><topic>Neurology</topic><topic>p16INK4a</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Polymorphism, Single-Stranded Conformational</topic><topic>Prognosis</topic><topic>promoter hypermethylation</topic><topic>Promoter Regions, Genetic - genetics</topic><topic>Soft Tissue Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawaguchi, Ken-ichi</creatorcontrib><creatorcontrib>Oda, Yoshinao</creatorcontrib><creatorcontrib>Saito, Tsuyoshi</creatorcontrib><creatorcontrib>Yamamoto, Hidetaka</creatorcontrib><creatorcontrib>Tamiya, Sadafumi</creatorcontrib><creatorcontrib>Takahira, Tomonari</creatorcontrib><creatorcontrib>Miyajima, Kimitaka</creatorcontrib><creatorcontrib>Iwamoto, Yukihide</creatorcontrib><creatorcontrib>Tsuneyoshi, Masazumi</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawaguchi, Ken-ichi</au><au>Oda, Yoshinao</au><au>Saito, Tsuyoshi</au><au>Yamamoto, Hidetaka</au><au>Tamiya, Sadafumi</au><au>Takahira, Tomonari</au><au>Miyajima, Kimitaka</au><au>Iwamoto, Yukihide</au><au>Tsuneyoshi, Masazumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>2003-11</date><risdate>2003</risdate><volume>201</volume><issue>3</issue><spage>487</spage><epage>495</epage><pages>487-495</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><coden>JPTLAS</coden><abstract>The p16INK4a tumour suppressor gene, encoding p16 protein, plays a crucial role in regulation of the G1 cell‐cycle phase. To investigate the potential role of p16 in soft tissue leiomyosarcoma (LMS), an immunohistochemical analysis was performed of 77 LMSs for p16 expression. Decreased expression of the p16 protein was identified in 25 of 77 LMSs (32%). Decreased expression of p16 correlated significantly with large tumour size (p = 0.0038). In a univariate analysis, large tumour size and decreased expression of p16 were statistically significant adverse prognostic factors (p = 0.025 and p = 0.0021, respectively). In a multivariate analysis including conventional clinicopathological parameters, decreased expression of p16 protein was revealed as the only independent unfavourable prognostic factor (p = 0.012). To elucidate the mechanisms of inactivation of the p16INK4a gene, 49 LMSs for which genomic DNA was available were examined; analysis for homozygous deletion, mutation, and promoter hypermethylation was conducted using differential PCR, PCR–SSCP, and methylation‐specific PCR, respectively. Promoter hypermethylation was detected in 11 of 49 LMS cases (22%); homozygous deletion was detected in 3 of 49 cases (6%); and mutation was not recognized in any of the cases studied. Eight of 15 cases (53%) with decreased expression of p16 protein revealed methylation of the p16INK4a gene promoter. Promoter hypermethylation correlated closely with decreased expression and poor prognosis (p = 0.0014 and p = 0.0088, respectively). These results suggest that decreased expression of p16 protein can be considered as an independent reliable prognostic parameter in patients with soft tissue LMS. Furthermore, promoter methylation was more frequent than either homozygous deletion or mutation in this tumour, and promoter methylation was also shown to have a strong association with inactivation of the p16INK4a gene. Copyright © 2003 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>14595762</pmid><doi>10.1002/path.1419</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3417 |
ispartof | The Journal of pathology, 2003-11, Vol.201 (3), p.487-495 |
issn | 0022-3417 1096-9896 |
language | eng |
recordid | cdi_proquest_miscellaneous_71358717 |
source | Wiley |
subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Child Cyclin-Dependent Kinase Inhibitor p16 - analysis Diseases of striated muscles. Neuromuscular diseases DNA Mutational Analysis - methods Female Gene Deletion Gene Expression Regulation, Neoplastic - genetics Genes, p16 Genes, Tumor Suppressor Homozygote homozygous deletion Humans immunohistochemistry Immunohistochemistry - methods leiomyosarcoma Leiomyosarcoma - genetics Male Medical sciences Methylation Middle Aged Neoplasm Proteins - analysis Neurology p16INK4a Polymerase Chain Reaction - methods Polymorphism, Single-Stranded Conformational Prognosis promoter hypermethylation Promoter Regions, Genetic - genetics Soft Tissue Neoplasms - genetics |
title | Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A15%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanisms%20of%20inactivation%20of%20the%20p16INK4a%20gene%20in%20leiomyosarcoma%20of%20soft%20tissue:%20decreased%20p16%20expression%20correlates%20with%20promoter%20methylation%20and%20poor%20prognosis&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Kawaguchi,%20Ken-ichi&rft.date=2003-11&rft.volume=201&rft.issue=3&rft.spage=487&rft.epage=495&rft.pages=487-495&rft.issn=0022-3417&rft.eissn=1096-9896&rft.coden=JPTLAS&rft_id=info:doi/10.1002/path.1419&rft_dat=%3Cproquest_pubme%3E71358717%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i1629-803a8dc6057960938eac50e29bf070c0c531c162bb5a7ea11688605147c4e1cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71358717&rft_id=info:pmid/14595762&rfr_iscdi=true |